7 completed, 6 recruiting, 2 enrolling by invitation, 2 not yet recruiting. 4 Not applicable, 4 Phase 2, 3 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 4 | Recruiting 2, Enrolling by invitation 1, Not yet recruiting 1 |
| Phase 2 | 4 | Completed 2, Recruiting 2 |
| Phase 1 | 3 | Completed 2, Withdrawn 1 |
| Phase 3 | 2 | Completed 2 |
Follow Fuchs Endothelial Corneal Dystrophy: new trials by email Literature Review of Fuchs Endothelial Corneal Dystrophy trials Research Report on Fuchs Endothelial Corneal Dystrophy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Partial Range Of Field IOLs in DMEK-Enabled Procedures combined cataract and lamellar endothelial keratoplasty - Cataract, Fuchs Endothelial Corneal Dystrophy | Not applicable | Not yet recruiting | Universitair Ziekenhuis Brussel | 10 | 2026-10-01 | 2026-08-25 |
| Postoperative CCT in FECD vs. Non-FECD Fuchs Endothelial Corneal Dystrophy, Cataract (Post-operative Cataract Surgery Follow-up) | Not yet recruiting | Vienna Hospital Association | 98 | 2026-07-20 | 2026-08-10 | |
| Effect of Descemet Membrane Polishing in Fuchs Endothelial Corneal Dystrophy Fuchs Polishing - Fuchs Endothelial Corneal Dystrophy | Not applicable | Recruiting | Centre Hospitalier Universitaire de Saint Etienne | 20 | 2026-05-21 | 2026-05-26 |
| Effect of Donor Diabetes and Other Factors on Corneal Transplant Endothelial Cell Loss and Success at 5 Years Descemet membrane endothelial keratoplasty - Fuchs Endothelial Corneal Dystrophy, Corneal Endothelial Decompensation | Not applicable | Enrolling by invitation | Case Western Reserve University | 570 | 2025-12-03 | 2026-02-27 |
| Influence of Supine Positioning on the Outcomes After Descemet Membrane Endothelial Keratoplasty (DMEK) Duration of Supine Positioning - Fuchs Endothelial Corneal Dystrophy, Descemet Membrane Endothelial Keratoplasty (DMEK) | Not applicable | Recruiting | University Hospital Heidelberg | 102 | 2025-10-02 | 2026-01-28 |
| DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy DT-168 - Fuchs Endothelial Corneal Dystrophy, Fuchs | Phase 2 | Recruiting | Design Therapeutics, Inc. | 70 | 2025-07-30 | 2026-09-28 |
| The Effect of Topical Rho-kinase Inhibitors on Corneas of Patients With Fuchs Endothelial Corneal Dystrophy Netarsudil 0.02% Ophthalmic Solution, artificial tear substitute - Fuchs Endothelial Corneal Dystrophy, Cataract | Enrolling by invitation | University Hospital Dubrava | 50 | 2025-04-01 | 2026-09-09 | |
| Comparison of Outcomes Between Femtosecond Laser-Assisted and Conventional Phacoemulsification in Fuchs Endothelial Corneal Dystrophy Patients With Cataracts Fuchs Endothelial Corneal Dystrophy, Cataract | Recruiting | Eye & ENT Hospital of Fudan University | 120 | 2025-01-01 | 2025-06-17 | |
| Prevalence of Fuchs Endothelial Corneal Dystrophy in a Population of Dermatology Patients. collection of medical data - Fuchs Endothelial Corneal Dystrophy | Completed | Centre Hospitalier Universitaire de Saint Etienne | 1200 | 2024-01-02 | 2025-08-12 | |
| A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD) Ripasudil, Placebo - Fuchs Endothelial Corneal Dystrophy | Phase 3 | Completed | Kowa Research Institute, Inc. | 110 | 2023-05-11 | 2026-01-22 |
| A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD) Ripasudil, Placebo - Fuchs Endothelial Corneal Dystrophy | Phase 3 | Completed | Kowa Research Institute, Inc. | 107 | 2023-03-30 | 2026-05-27 |
| A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD) STN1010904 ophthalmic suspension 0.03% BID, STN1010904 ophthalmic suspension 0.1% BID, Placebo (Vehicle) BID - Fuchs Endothelial Corneal Dystrophy | Phase 2 | Completed | Santen Inc. | 86 | 2022-05-19 | 2026-08-07 |
| Study With QR-504a to Evaluate Safety, Tolerability & Corneal Endothelium Molecular Biomarker(s) in Subjects With FECD3 QR-504a - Fuchs Endothelial Corneal Dystrophy, FECD3 | Phase 1 | Withdrawn | ProQR Therapeutics | 2021-08-10 | 2022-05-11 | |
| Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema EO2002, EO2002 low dose, EO2002 mid dose - Corneal Edema, Corneal Endothelial Dysfunction | Phase 1 | Completed | Emmecell | 42 | 2021-06-22 | 2025-03-05 |
| Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy N-acetyl cysteine (NAC) 10% solution, N-acetyl cysteine (NAC) 20% solution, Visine Dry Eye Relief eye drops - Fuchs Endothelial Corneal Dystrophy | Phase 2 | Recruiting | Massachusetts Eye and Ear Infirmary | 45 | 2020-09-16 | 2026-09-02 |
| A Phase 1/ Phase 2 Study of TTHX1114(NM141) TTHX1114(NM141), Vehicle (placebo) - Corneal Endothelial Dystrophy, Fuchs Endothelial Corneal Dystrophy | Phase 1 / Phase 2 | Completed | Trefoil Therapeutics, Inc. | 22 | 2020-08-19 | 2023-10-30 |
| SUCCESS Score Validation in Fuchs Dystrophy Phacoemulsification Cataract Surgery - Fuchs Endothelial Corneal Dystrophy | Recruiting | Instituto Ramón y Cajal de Investigación Sanitaria | 250 | 2020-06-01 | 2025-12-04 | |
| The Postoperative Head Position as a Predictor of the Surgical Outcome After DMEK Fuchs Endothelial Corneal Dystrophy, Pseudophakic Bullous Keratopathy | Unknown | Peter Wiedemann | 50 | 2020-05-11 | 2020-05-13 | |
| Analysis of the Genotype/Phenotype Relationship in the Fuchs' Corneal Endothelial Dystrophy in France. Collection of datas, blood sample, slit lamp examination - Fuchs Endothelial Corneal Dystrophy | Completed | Centre Hospitalier Universitaire de Saint Etienne | 208 | 2019-08-01 | 2023-04-18 |
Fuchs' Endothelial Dystrophy (19) · Cataract (4) · Corneal Dystrophy, Posterior Polymorphous, 1 (3) · Corneal Diseases (2) · Corneal Edema (2) · Carcinoma (1) · Glaucoma (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (19) · Corneal Dystrophies, Hereditary (19) · Eye Diseases (19) · Eye Diseases, Hereditary (19) · Genetic Diseases, Inborn (19) · Corneal Diseases (17) · Lens Diseases (4) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms, Glandular and Epithelial (1) · Ocular Hypertension (1)
K-115 (2) · Acetylcysteine (1) · BID protein, human (1) · Blood Specimen Collection (1) · Ophthalmic Solutions (1) · Slit Lamp (1) · Solutions (1) · netarsudil (1)
Centre Hospitalier Universitaire de Saint Etienne (3) · Kowa Research Institute, Inc. (2) · Case Western Reserve University (1) · Design Therapeutics, Inc. (1) · Emmecell (1) · Eye & ENT Hospital of Fudan University (1) · Instituto Ramón y Cajal de Investigación Sanitaria (1) · Massachusetts Eye and Ear Infirmary (1) · Peter Wiedemann (1) · ProQR Therapeutics (1) · Santen Inc. (1) · Trefoil Therapeutics, Inc. (1) · Universitair Ziekenhuis Brussel (1) · University Hospital Dubrava (1) · University Hospital Heidelberg (1)
United States (8) · France (4) · Germany (4) · Spain (3) · United Kingdom (3) · Canada (2) · Denmark (2) · Belgium (1) · China (1) · Croatia (1) · India (1)
Shona Pendse, MD, MMSc (2) · Jonathan Lass, MD (1) · Josip Pavan, prof.dr.sc. (1) · Karolien Termote, MF, Febo (1) · Noelia Kunzevitzky (1) · Peter Wiedemann, MD (1) · Thomas M Tremblay, RN BSN (1) · Ula Jurkunas, MD (1)
PMID 33951443, PMID 35462618, PMID 36637659, PMID 39288343, PMID 39320570, PMID 39661178, PMID 9071233
1UG1EY037206-01 (1), 5UG1EY030030-05 (1)